Traws Pharma (TRAW) Expected to Post Quarterly Earnings on Thursday

Traws Pharma (NASDAQ:TRAW) is anticipated to issue its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Traws Pharma to post earnings of ($0.3350) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 20, 2026 at 8:30 AM ET.

Traws Pharma (NASDAQ:TRAW) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.53) EPS for the quarter, topping analysts’ consensus estimates of ($0.92) by $0.39. On average, analysts expect Traws Pharma to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Traws Pharma Price Performance

Shares of TRAW opened at $0.54 on Wednesday. Traws Pharma has a 1 year low of $0.43 and a 1 year high of $3.27. The company has a 50 day simple moving average of $0.78 and a two-hundred day simple moving average of $1.41. The firm has a market cap of $8.20 million, a P/E ratio of -0.32 and a beta of 1.57.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of TRAW. Two Sigma Investments LP grew its holdings in shares of Traws Pharma by 37.1% in the third quarter. Two Sigma Investments LP now owns 22,018 shares of the company’s stock valued at $41,000 after purchasing an additional 5,955 shares in the last quarter. Geode Capital Management LLC raised its stake in Traws Pharma by 41.9% during the fourth quarter. Geode Capital Management LLC now owns 61,653 shares of the company’s stock valued at $70,000 after purchasing an additional 18,213 shares in the last quarter. State Street Corp purchased a new stake in Traws Pharma during the fourth quarter valued at $29,000. Adage Capital Partners GP L.L.C. lifted its position in Traws Pharma by 121.2% during the fourth quarter. Adage Capital Partners GP L.L.C. now owns 730,000 shares of the company’s stock valued at $825,000 after purchasing an additional 400,000 shares during the last quarter. Finally, ADAR1 Capital Management LLC bought a new position in Traws Pharma during the fourth quarter valued at $175,000. 7.95% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

Several equities analysts have recently commented on TRAW shares. HC Wainwright reissued a “negative” rating and issued a $1.00 target price on shares of Traws Pharma in a report on Thursday, June 18th. Wall Street Zen raised shares of Traws Pharma from a “strong sell” rating to a “sell” rating in a research note on Saturday, June 13th. LADENBURG THALM/SH SH downgraded shares of Traws Pharma from a “buy” rating to a “neutral” rating in a report on Monday, June 15th. Weiss Ratings downgraded shares of Traws Pharma from a “sell (d)” rating to a “sell (e+)” rating in a report on Friday, May 29th. Finally, Citigroup cut shares of Traws Pharma to a “neutral” rating in a research note on Monday, June 15th. Three equities research analysts have rated the stock with a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, Traws Pharma has an average rating of “Reduce” and an average price target of $1.00.

Traws Pharma Company Profile

Traws Pharma, Inc, a clinical stage biopharmaceutical company, focuses on developing small molecule oral product candidates for respiratory viral diseases and cancer. The company is developing investigational novel therapies for influenza and COVID19 that are designed to address treatment resistance, such as TRX01 (travatrelvir), a Mpro/3CL inhibitor in development for the treatment of COVID19; and TRX100 (viroxavir), an endonuclease inhibitor in development for the treatment of pandemic influenza.